Investor Presentation - First Six Months of 2021
88
Investor presentation
First six months of 2021
International Operations at a glance.
Novo NordiskⓇ
Diabetes trend
Million
700
DKK
billion
22%
200
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First half of 2021
Sales
(MDKK)
Growth²
80%
Total GLP-13
7,527
46%
600
I
26%
Long-acting insulin4
5,602
14%
GLP-1
150
500
60%
Premix insulin5
5,393
6%
29%1
I
Fast-acting insulin
5,508
4%
400
Insulin
Human insulin
3,837
(1%)
100
40%
300
637
Total insulin
20,340
6%
4%1
522
Other Diabetes care?
1,427
(3%)
200
415
50
20%
Diabetes care
29,294
13%
100
8%1
OAD
Obesity care
1,497
44%
(SaxendaⓇ)
0
2019
2030
0
May
2045
2016
0%
Diabetes & Obesity
30,791
15%
May
2021
care
Population with diabetes
O Diabetes growth rate
Biopharm³
6,193
4%
GLP-1 MS -Insulin MS
-OAD MS
Total
36,984
13%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of May 2021: Novo Nordisk 50%, Sanofi 28% and Eli Lilly 14%;
Competitor GLP-1 value market shares, as of May 2021: Novo Nordisk
56%, Eli Lilly 40% and AstraZeneca 3%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, May 2021 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises RyzodegⓇ and
NovoMix: 6 Comprises Fiasp® and NovoRapid®; 7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily NovoSeven®, Novo Eight® NovoThirteenⓇ,
Refixia®, Esperoct®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation